CCM3 Antibody (C-8): sc-365586
- CCM3 Antibody (C-8) is a mouse monoclonal IgG2b κ CCM3 antibody, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 3-191 mapping within an internal region of CCM3 of human origin
- CCM3 Antibody (C-8) is recommended for detection of CCM3 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- Anti-CCM3 Antibody (C-8) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP, m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CCM3 Antibody (C-8) for WB and IHC(P) applications. These reagents are now offered in bundles with CCM3 Antibody (C-8) (see ordering information below).
QUICK LINKS
SEE ALSO...
CCM3 Antibody (C-8) is a mouse monoclonal IgG2b kappa light chain antibody that detects CCM3 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). CCM3 (C-8) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CCM3, also known as Pdcd-10, plays a crucial role in the regulation of programmed cell death, which is vital for processes such as embryogenesis, tissue turnover, and proper functioning of the immune system. Located primarily in the cytoplasm, CCM3 interacts with key signaling pathways, particularly the ERK pathway, where CCM3 positively regulates MST4, thereby promoting cell growth and differentiation. This regulation is essential for vascular development and maturation, and defects in CCM3 gene can lead to cerebral cavernous malformations 3 (CCM3), a condition characterized by vascular anomalies in the central nervous system that may result in severe complications such as stroke, seizures, and focal hemorrhages. Anti-CCM3 antibody (C-8) versatility in various applications makes CCM3 (C-8) monoclonal antibody an invaluable tool for researchers studying the mechanisms of apoptosis and vascular biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CCM3 Antibody (C-8) References:
- Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. | Bergametti, F., et al. 2005. Am J Hum Genet. 76: 42-51. PMID: 15543491
- Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3. | Guclu, B., et al. 2005. Neurosurgery. 57: 1008-13. PMID: 16284570
- Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. | Liquori, CL., et al. 2006. Hum Mutat. 27: 118. PMID: 16329096
- CCM3 mutations are uncommon in cerebral cavernous malformations. | Verlaan, DJ., et al. 2005. Neurology. 65: 1982-3. PMID: 16380626
- Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. | Petit, N., et al. 2006. Gene Expr Patterns. 6: 495-503. PMID: 16455310
- Molecular genetics of familial cerebral cavernous malformations. | Dashti, SR., et al. 2006. Neurosurg Focus. 21: e2. PMID: 16859255
- PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway. | Ma, X., et al. 2007. Mol Biol Cell. 18: 1965-78. PMID: 17360971
- CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. | Voss, K., et al. 2007. Neurogenetics. 8: 249-56. PMID: 17657516
- Proteomic identification of the cerebral cavernous malformation signaling complex. | Hilder, TL., et al. 2007. J Proteome Res. 6: 4343-55. PMID: 17900104
- CCM3 and cerebral cavernous malformation disease. | Wang, K., et al. 2019. Stroke Vasc Neurol. 4: 67-70. PMID: 31338212
- The multifaceted PDCD10/CCM3 gene. | Valentino, M., et al. 2021. Genes Dis. 8: 798-813. PMID: 34522709
- CCM3 Loss-Induced Lymphatic Defect Is Mediated by the Augmented VEGFR3-ERK1/2 Signaling. | Qin, L., et al. 2021. Arterioscler Thromb Vasc Biol. 41: 2943-2960. PMID: 34670407
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CCM3 Antibody (C-8) | sc-365586 | 200 µg/ml | $322.00 | |||
CCM3 Antibody (C-8): m-IgG Fc BP-HRP Bundle | sc-529395 | 200 µg Ab; 10 µg BP | $361.00 | |||
CCM3 Antibody (C-8): m-IgGκ BP-HRP Bundle | sc-522275 | 200 µg Ab, 40 µg BP | $361.00 | |||
CCM3 Antibody (C-8): m-IgG2b BP-HRP Bundle | sc-550104 | 200 µg Ab; 10 µg BP | $361.00 | |||
CCM3 Antibody (C-8) AC | sc-365586 AC | 500 µg/ml, 25% agarose | $424.00 | |||
CCM3 Antibody (C-8) HRP | sc-365586 HRP | 200 µg/ml | $322.00 | |||
CCM3 Antibody (C-8) FITC | sc-365586 FITC | 200 µg/ml | $336.00 | |||
CCM3 Antibody (C-8) PE | sc-365586 PE | 200 µg/ml | $349.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 488 | sc-365586 AF488 | 200 µg/ml | $364.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 546 | sc-365586 AF546 | 200 µg/ml | $364.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 594 | sc-365586 AF594 | 200 µg/ml | $364.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 647 | sc-365586 AF647 | 200 µg/ml | $364.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 680 | sc-365586 AF680 | 200 µg/ml | $364.00 | |||
CCM3 Antibody (C-8) Alexa Fluor® 790 | sc-365586 AF790 | 200 µg/ml | $364.00 |